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Abstract
Endothelial nitric oxide (NO) is a significant signaling molecule that regulates cerebral blood flow (CBF), playing a
pivotal role in the prevention and treatment of cerebrovascular diseases. However, achieving the expected
therapeutic efficacy is difficult using direct administration of NO donors. Therefore, endothelial nitric oxide synthase
(eNOS) becomes a potential therapeutic target for cerebrovascular diseases. This review summarizes the current
evidence supporting the importance of CBF to cerebrovascular function, and the roles of NO and eNOS in CBF
regulation.
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Background
Cerebrovascular diseases are various vascular diseases of
the cerebral circulation. Disrupted arterial oxygen supply to
the brain results in cerebrovascular diseases such as transi-
ent ischemic attack, stroke, subarachnoid hemorrhage and
vascular dementia. Many mechanisms contribute to the
complex pathophysiological process. Cerebrovascular dis-
eases have become the major causes of long-term disability
and mortality throughout the world.
Currently, the treatment of cerebrovascular diseases
includes thrombolytic therapy, anti-platelet aggregation
drugs, anticoagulants and neuroprotective agents. However,
these treatments all have major limitations, including a
short treatment time window, side effects, complications,
long-term medication and heavy expenses. Therefore, cere-
brovascular diseases are not only substantial medical bur-
dens, but also heavy economic and social burdens. These
burdens have stimulated tireless efforts to prevent and cure
cerebrovascular diseases, and in particular to define the role
of cerebrovascular endothelium in the pathogenesis of cere-
brovascular diseases. Cerebrovascular endothelium, as a
vascular barrier contacting blood directly, is injured first by
vascular risk factors and subsequently forms various cere-
brovascular diseases. Interestingly, brain microvascular
endothelial cells (BMECs), known as the body’s largest
endocrine, paracrine and metabolic organ, can generate
and release many vasoactive substances. These include
nitric oxide (NO) and endothelin-1 (ET-1), which maintain
cerebrovascular homeostasis [1]. In addition, cerebrovascu-
lar endothelium plays a critical role in the regulation of
cerebral blood flow (CBF). It does so partially through syn-
thesis of NO, a major vasodilator, from L-arginine, by the
catalytic reaction of enzyme endothelial nitric oxide syn-
thase (eNOS). Adequate CBF is one of the basic conditions
for normal brain function. Endothelial NO production
mainly depends on the eNOS activity; therefore, eNOS acti-
vation in cerebrovascular endothelium should not be ig-
nored. A recent study has found that in patients exposed to
vascular risk factors, endothelium-dependent relaxation
dysfunction was detectable before any morphological
changes on the vessel wall, implying vascular endothelium
is the first to be damaged. More importantly, different risk
factors for cerebrovascular diseases including hypertension,
hypercholesterolemia, diabetes, aging, smoking, and obesity
could all impair contraction and dilation of cerebrovascular
endothelium [2]. Therefore, eNOS as an important regula-
tor of cerebrovascular endothelium functions should be
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recognized as a potential therapeutic target for the preven-
tion and treatment of cerebrovascular diseases.
Cerebral blood flow and neurological function
The brain consumes 20 % of the body’s energy and nutri-
ents. The basilar artery loop connects to the common
carotid artery and is spread over almost all of the brain
with numerous branches (the anterior middle and poster-
ior cerebral arteries). The branches extend from soft
membrane to the white matter constituting the cerebro-
vascular system. This system plays an irreplaceable role in
supporting the brain by providing it with oxygen and nu-
trients. Under normal physiological conditions, the brain
can maintain adequate CBF through its vascular autoregu-
latory mechanisms in order to support the energy needs
of its cellular constituents. However, many pathological
conditions including cerebral ischemia, trauma, stroke,
and vasospasm after subarachnoid hemorrhage (SAH)
cause abnormal CBF, subsequently inducing diverse brain
disorders. Abnormalities in cerebral hemodynamics, such
as changes in local perfusion pressure and vascular integ-
rity, are important pathophysiological elements in ische-
mic stroke. This may further damage neurons or glial cells
beyond the initial ischemia injury caused by either hypo-
or hyperperfusion [3]. Existing evidence suggests that the
cerebrovascular endothelial dysfunction, induced by cere-
bral ischemia and anoxia-caused vasospasm and/or
thrombosis, will further reduce CBF. Continuously de-
creased CBF can gradually cause learning and memory
disorders and cognitive dysfunction, leading to the de-
velopment of dementia [4–6]. Thus, the regulation of
CBF is closely related to neurological function. Dilation
of blood vessels is an important way to improve CBF.
Vascular endothelial cells regulate the vasodilatation by
synthesis and secretion of cytokines, such as PGI2 and
NO. Studies have shown that the endothelial NO gener-
ated in cerebrovascular endothelium is one of the most
important signaling molecules of CBF autoregulatory
mechanisms [7, 8].
Endothelial oxide synthase in cerebrovascular regulatory
mechanisms
As mentioned above, the brain is endowed with vasoregu-
latory mechanisms that assure it receives enough blood to
support its energy expenditure. Endothelial NO is one of
the most pivotal signaling molecules in these mechanisms
(Fig. 1) [7, 8]. It is involved in preserving and maintaining
the brain’s microcirculation, inhibiting platelet aggrega-
tion, leukocyte adhesion and migration, and reducing
smooth muscle proliferation. NO plays a pivotal role in
regulating cerebrovascular effects by increasing or de-
creasing oxygen, and elevating carbon dioxide, carbon
monoxide and cerebrovascular autoregulation [9, 10]. It is
generally acknowledged that the loss of endothelial NO is
Fig. 1 Endothelial oxide synthase (eNOS) and its role in cerebral blood flow (CBF) regulatory mechanisms. eNOS is activated by Acetylcholine
(ACh), bradykinin, shear stress, etc., and then catalyzes L-arginine to generate NO. It translates into vascular smooth muscle cells, reacts with
guanylate cyclase (GC), and promotes the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), resulting in
vascular smooth muscle relaxation and the CBF increase
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the central mechanism in the pathogenesis of endothelial
dysfunction. In both cerebral and peripheral vasculatures,
reduced availability of endothelial NO will result in major
detrimental alterations of vascular functions. These
include vasoconstriction, an increase in arterial blood
pressure, proliferation of vascular smooth muscle cells
(VSMCs), platelet aggregation, white blood cell adhesion,
and inflammation. Reduced availability of endothelial NO
plays an essential role in the initiation and progression of
vascular diseases such as atherosclerosis. Therefore,
preserving endothelial NO production is an important
strategy for the prevention of cerebrovascular diseases
[11]. However, diverse vascular risk factors can directly or
indirectly reduce endothelial NO production. Oxidative
stress caused by excessive production of reactive oxygen
species (ROS) and primarily superoxide anions is consid-
ered to be the most important mechanism of reducing
endothelial NO. On one hand, vascular risk factors pro-
mote the up-regulation of NADPH-oxidase activity, gener-
ation of superoxide anions, chemical inactivation of NO,
and generation of a potent oxidant, peroxynitrite [12]. On
the other hand, oxidative stress induced by increased
peroxynitrite production may oxidize tetrahydrobiopterin
(BH4), an essential co-factor required for eNOS activity. If
the concentration of BH4 becomes suboptimal, the eNOS
dimer will uncouple from other eNOS monomers, result-
ing in reducing the production of endothelial NO and
increasing the production of superoxide anions and perox-
ynitrite [13]. It is reported that decreased arterial oxygen
supply (hypoxia) increases the CBF baseline in humans
[14]. Thus, NO plays a significant role in both the signal-
ing event and the CBF response [15]. Conversely, nonse-
lective NOS inhibition abolishes the CBF increase
response to hypoxia in rats [16]. It follows that the NO
signaling pathway plays a central role in the CBF response
to these alterations, and this post-ischemia pathway
dysfunction causes dysregulation of these normal physio-
logical responses. Recent studies on CBF regulation by
endothelial NO have provided new insights about the
physiological control of cerebrovascular functions and the
pathological mechanisms of neurological diseases. They
also supply new clues for developing novel therapeutic
strategies for cerebral dysfunction [9]. Indeed, eNOS has
been paid even more attention than NO because of the in-
stability of NO and the regulatory mechanisms of eNOS
on NO production.
Endothelial nitric oxide synthase and cerebrovascular
diseases
eNOS function
Innate eNOS activity determines susceptibility to in-
jury due to its conferring protection against secondary
neuronal damage. Impairment of eNOS activity by
SAH, traumatic brain injury (TBI) and ischemic stroke
has been implicated in many cellular mechanisms of
neuronal injury [17].
Delayed cerebral ischemia (DCI) is one of the major
causes of morbidity and mortality following SAH. A recent
study has demonstrated that the pathogenesis of DCI in-
volves the NO signaling pathway [18]. Meanwhile, genetic
variation in the eNOS gene in humans influences the risk
of DCI after SAH, because T-786C single nucleotide poly-
morphism of the eNOS gene promoter can cause lower
eNOS activity and result in greater risk [19, 20].
eNOS also plays an important role in maintaining CBF
after TBI. Patients with decreased endogenous eNOS
levels have poorer outcomes than patients with alleles
that do not affect eNOS levels [21]. A previous study
has suggested that the immunoreactivity of eNOS is in-
creased in the microvasculature surrounding the area of
impact in the first 3 days after experimental trauma [22].
However, eNOS knockout mice have greater reduction
in CBF than wildtype variants in the first 2 h after
trauma [23]. Genetic variants of eNOS also influence the
maintenance of CBF after severe TBI.
Ischemic stroke is most often caused by a throm-
botic or embolic blockage of a cerebral artery, which
causes blood flow interruption and tissue death. Stud-
ies have found that thrombotic cerebral infarctions
appear in eNOS+/− mice as early as 3–6 months of
age. eNOS knockout mice have bigger infarcts than
wildtype variants after ischemic stroke caused by middle
cerebral artery occlusion (MCAO) [24, 25]. In contrast, the
administration of NO precursor (L-arginine) or donors (so-
dium nitroprusside (SNP) and 3-morpholino sydnonimine)
to rat MCAO models of focal ischemia have improved CBF,
prevented cerebral tissue necrosis and decreased brain ATP
and glutamate levels. This appears to be time-dependent
and limited to the first 30 min after ischemic onset. During
this period, NO elicits vasodilatory effects, improves CBF
and reduces the infarct size, while it evokes neurovascular
toxicity beyond this point [25–27]. Moreover, eNOS not
only promotes vasodilation but also increases the prolifera-
tion and migration of VSMCs, thereby enhancing arterio-
genesis after stroke [28]. Activation of eNOS mediates
protection from stroke by preserving CBF and inhibiting in-
flammation, platelet aggregation, thrombosis, and apoptosis
[11]. Continuous voluntary running confers long-term up-
regulation of eNOS in the vasculature and higher numbers
of circulating endothelial progenitor cells (EPCs) in the
blood. This nevertheless enhances neovascularization and
CBF by eNOS-dependent mechanisms after brain ischemia
[29]. eNOS is also essential for mobilization of EPCs. The
impaired neovascularization in mice lacking eNOS is re-
lated to a defect in progenitor cell mobilization [30].
Uncoupled eNOS in the cerebral arteries has been re-
ported to participate in hypoxic-ischemic brain injury by
inducing oxidative stress under ischemia [31]. Uncoupling
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of eNOS emerges from an absence of either its substrate
L-arginine, and/or co-factor BH4, which is required for
coupling of the two functional eNOS subunits. This is
known to be a common phenomenon in many diseases,
such as hypertension, diabetes, and hypercholesterolemia
[32, 33]. In an uncoupled state, the electron flow inside
the eNOS peptide is diverted to the molecular oxygen,
thereby leading to an uncontrolled eNOS uncoupling and
enhanced O2
•- production. In summary, normal eNOS
function is vital to alleviate cerebrovascular diseases.
Regulatory mechanisms of eNOS activity
eNOS has a homologous dimerized structure consist-
ing of two identical subunits. Each subunit contains a
C-terminal reductase domain and an N-terminal oxy-
genase domain. The former contains binding sites for
NADPH, flavin adenine dinucleotide (FAD), and flavin
mononucleotide (FMN), in close homology with cyto-
chrome P-450 reductase; the latter binds heme, BH4,
and the substrate L-arginine. Between these two re-
gions lies the calmodulin (CaM) binding domain,
which plays a key role in both the structure and func-
tion of the enzyme. To obtain full catalytic activity
under physiological conditions, separate N-terminal
oxygenase and C-terminal reductase domains of eNOS
must be joined together in the presence of heme, BH4
and Ca2+/CaM complex [7, 34]. Many studies suggest
that the enzyme is generally activated by an increase
in intracellular Ca2+ via either influx of extracellular
Ca2+ or release from intracellular storage sites. How-
ever, eNOS activation is also independent of Ca2+,
while activated by mechanical forces, including shear
stress, cyclic strain, and G protein [35–37].
The regulatory mechanisms of eNOS activity are ex-
tremely complex, and can be divided into the genetic and
protein level (Fig. 2). At the genetic level, the expression
and stability of eNOS genes are related to eNOS activity.
The eNOS promoter contains a large number of sites for
the binding of transcription factors, including activator
protein-1 (AP-1), activator protein-2 (AP-2), endothelin
family, nuclear factor-κB (NF-κB), and neurofibromin 1
(NF-1). These transcription factor complexes can regulate
eNOS expression. In addition, hypoxia, lipopolysaccharide
and several cytokines can induce the expression of two
kinds of eNOS cytoplasmic proteins. They bind to the 3′
untranslated region of eNOS mRNA rich in cytosine,
subsequently leading to configuration changes and RNA
enzyme activation, which cause lower eNOS mRNA stabil-
ity and shorter half-life. Many factors, such as hypoxia,
estrogen, and exercise are now known to affect eNOS
expression [38–40]. At the protein level, regulatory mecha-
nisms mainly include eNOS translocation, complex
Fig. 2 The regulatory mechanisms of eNOS activity. The mechanisms work at both the genetic and protein level. At the genetic level, nuclear
factor-κB (NF-κB), activator protein-1 (AP-1), activator protein-2 (AP-2), Krűppel-like Factor 2 (KLF2), endothelin family and Forkhead box O1 (Foxo-1)
genes regulate eNOS expression; at the protein level, several factors, such as bradykinin, 5-hydroxytryptamine (5-HT), ACh, shear stress, and high density
lipoprotein (HDL), promote eNOS phosphorylation by PI3K/Akt, AMPK and MAPK pathways. In addition, binding with calmodulin (CaM) enhances eNOS
activation, while caveolin-1(Cav-1) inhibits eNOS activation
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formation and the phosphorylation of the amino acid resi-
dues. The association of eNOS with bradykinin B2 receptor
and caveolin-1(Cav-1) in the caveolae and microdomains of
the endothelial plasma membrane leads to inhibition of
eNOS activity. This inhibition is apparently the result of
functional interference with CaM binding and electron
transfer [41, 42].
Cav-1 on cell membrane binds to not only the oxygen-
ase domain but also the reductase domain of eNOS.
Binding of Cav-1 to the eNOS reductase domain inhibits
the combination of heme iron with eNOS, and prevents
electron transfer from the reductase. In eNOS the Cav-1
binding motif lies between the heme and the CaM bind-
ing domains adjacent to a glutamate residue (Glu-361), a
necessary site for the binding of L-arginine [42–44].
Thus, Cav-1 binding to eNOS inhibits the trafficking
and activation of eNOS. Two new-found proteins, eNOS
interacting protein (NOSIP) and eNOS traffic inducer
(NOSTRIN), have been confirmed to interact with eNOS
and Cav-1 to form a ternary complex. The complex then
induces eNOS migration from the plasma membrane
and significantly reduces eNOS activity [45–47].
Present studies show that eNOS phosphorylation occurs
in its serine, threonine and tyrosine residues. Within these
residues, the phosphorylation of the Thr495, Ser633 and
Ser1177 sites have the most significant influences on
eNOS activity. The phosphorylation of the Thr495 site
prevents CaM binding to eNOS, thereby reducing eNOS
activity [48], while the phosphorylation of the Ser1177 site
enhances the catalytic ability of eNOS through inhibiting
the separation of CaM and eNOS, and increases the in-
ternal electron transfer rate of eNOS; the phosphorylation
of the Ser633 site also enhances eNOS activity [49–51].
The threonine protein kinase (Akt/PKB) is an important
determinant of the phosphorylation of the eNOS Ser1177
site, which is involved in the basic activation of eNOS and
its agonist activation [52, 53].
Akt mainly resides in the cytoplasm inactively; trans-
location to the cell membrane induces its activation
and the phosphorylation of eNOS [54]. It is directly
controlled by the phosphatidylinositol-3 kinase serine
(PI3K)-dependent phosphorylation pathway. PI3K re-
cruits Akt to cell membrane and phosphorylates it [55].
Bradykinin and 5-hydroxytryptamine (5-HT) act with
membrane receptors, leading to the increase of cyto-
plasmic Ca2+ concentration and activation of CaM. It
first promotes eNOS uncoupling with Cav-1; eNOS
then couples with CaM to form an eNOS/CaM com-
plex and translocates to the cytoplasmic membrane.
After translocation, the eNOS/CaM complex induces
phosphorylation of eNOS amino acid residues at the
Ser1177 site and dephosphorylation at the Thr495 site
through the Akt/PKB pathway, resulting in eNOS acti-
vation [56–58].
Meanwhile, after cytoplasmic Ca2+ concentration in-
creases, Ca2+/calmodulin- dependent protein kinase
kinase-β (CaMKKβ), an alternative upstream kinase for
adenosine 5′-monophosphate (AMP)-activated protein
kinase (AMPK) and a key molecule of the AMPK signal-
ing pathway, induces the phosphorylation of AMPK at
the Thr172 site. Upon activation, AMPK promotes the
phosphorylation of eNOS at the Ser1177 and/or Ser633
sites, enhances eNOS activity and promotes NO synthe-
sis. It is restrained by Compound C, a specific inhibitor
of AMPK [59–63]. Interestingly, eNOS Ser1177 phos-
phorylation has dual functions after ischemic stroke.
eNOS expression, eNOS Ser1177 phosphorylation and
eNOS monomer formation is increased in the acute
phase, but Ser1177 phosphorylation is markedly de-
creased in the later phases of ischemia. Uncoupling of
eNOS is significantly increased in this phase. Because
eNOS dysfunction contributes to secondary injury and
inhibits tissue repair, dephosphorylation and monomer
formation of eNOS may become a potential therapeutic
target of cerebral ischemia in the later phases [64]. The
Ser1177 site may be the more important targeting mech-
anism compared with the Ser633 site.
Furthermore, eNOS can be activated by either shear
stress through phosphorylation of Ser1177 via the PI3K/
Akt pathway [50], or by high density lipoprotein (HDL)
modification by Akt kinase and mitogen-activated pro-
tein kinase (MAPK) [65].
In summary, the Ser1177and Ser633 sites may be po-
tential therapeutic target sites. Regulating the phosphor-
ylation of these two sites and the eNOS activation are
regulatory mechanisms for CBF.
The candidates for eNOS targeted therapy
Recent studies have demonstrated that statins have a
potential to enhance the bioavailability of endothelium-
derived NO, principally by up-regulating and activating
eNOS. This is mediated by diverse signaling, such as
Rho/ROCK, PI3K/Akt, caveolin, ERK 1/2, and so on
[66, 67]. Similarly, atorvastatin and simvastatin could
increase eNOS expression by inhibiting Rho-kinase and
increasing Ras-mediated activation of the PI3K-Akt and
ERK1/2-RSK signaling pathways, respectively [68, 69].
Additionally, the Rho-kinase inhibitor fasudil amelio-
rates brain tissue injury via rapid augmentation of
eNOS phosphorylation, suppressing eNOS dephosphor-
ylation and monomerization in the ischemic brain [64].
Conclusion
NO is an important mediator in the regulation of CBF.
However, the NO signaling pathway influences the evo-
lution of multiple aspects of secondary brain injury and
interacts with many other signaling pathways, which
makes it difficult to translate results from animal models
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to patients. A systematic review of NO donor adminis-
tration during animal stroke models demonstrates an
overall improvement in CBF and a decrease in infarction
volume [70]. However, whether these results can be
translated into patients with cerebral ischemia/reperfu-
sion injury (e.g. ischemic stroke, cardiac arrest) has not
yet been tested [71]. It is also likely that many of the
neuroprotective effects of NO donors are the result of
not only the improvement of CBF, but also the NO do-
nors’ metabolic and cellular effects.
Therefore, it is difficult to use direct administration of
NO donors to achieve the expected therapeutic efficacy.
As a key enzyme of NO synthase, eNOS becomes a po-
tential therapeutic target for the prevention and treat-
ment of cerebrovascular diseases. There is numerous
evidence to suggest that NO derived from eNOS is neu-
roprotective after an acquired brain injury. The modula-
tion of eNOS during and/or following ischemic injury
often represents a futile compensatory mechanism due
to a significant decrease in NO bioavailability, coupled
with a dramatic increase in the ROS levels that further
neutralize NO [19]. Thus, the modulation of eNOS used
in combination with an antioxidant may be significantly
more effective. A better understanding of the roles of
eNOS might lead to the development of exciting new
pharmacotherapies to mitigate secondary brain injury,
with the aim of reducing the morbidity and mortality
from cerebrovascular diseases.
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